Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 157
Filtrar
1.
Anticancer Res ; 39(12): 6661-6671, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31810931

RESUMO

BACKGROUND: Boron neutron capture therapy (BNCT) selectively kills tumor cells while sparing adjacent normal cells. Boric acid (BA)-mediated BNCT showed therapeutic efficacy in treating hepatocellular carcinoma (HCC) in vivo. However, DNA damage and corresponding responses induced by BA-mediated BNCT remained unclear. This study aimed to investigate whether BA-mediated BNCT induced DNA double-strand breaks (DSBs) and to explore DNA damage responses in vitro. MATERIALS AND METHODS: Huh7 Human HCC cells were treated with BA and irradiated with neutrons during BA-BNCT. Cell survival and DNA DSBs were examined by clonogenic assay and expression of phosphorylated H2A histone family member X (γH2AX), respectively. The DNA damage response was explored by determining the expression levels of DNA repair- and apoptosis-associated proteins and conducting a cell-cycle analysis. RESULTS: DNA DSBs induced by BA-mediated BNCT were primarily repaired through the homologous recombination pathway. BA-mediated BNCT induced G2/M arrest and apoptosis in HCC. CONCLUSION: Our findings may enable the identification of radiosensitizers or adjuvant drugs for potentiating the therapeutic effectiveness of BA-mediated BNCT for HCC.


Assuntos
Ácidos Bóricos/uso terapêutico , Terapia por Captura de Nêutron de Boro/métodos , Carcinoma Hepatocelular/radioterapia , Quebras de DNA de Cadeia Dupla , Reparo do DNA , Neoplasias Hepáticas/radioterapia , Radiossensibilizantes/uso terapêutico , Proteínas Reguladoras de Apoptose/metabolismo , Ácidos Bóricos/farmacocinética , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Caspase 3/metabolismo , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos da radiação , Reparo do DNA por Junção de Extremidades , Proteínas de Ligação a DNA/metabolismo , Ativação Enzimática , Histonas/metabolismo , Humanos , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Radiossensibilizantes/farmacocinética , Reparo de DNA por Recombinação
2.
Prog. obstet. ginecol. (Ed. impr.) ; 62(3): 221-229, mayo-jun. 2019. tab, graf
Artigo em Inglês | IBECS | ID: ibc-185002

RESUMO

Objective: To demonstrate that vaginal application of boric acid and probiotics is effective for the treatment of vulvovaginitis and can be considered not only an alternative option, but also a first-line treatment.Material and methods: We performed a multicenter, open-label, pilot trial with random allocation to the study treatment (150 mg boric acid + Lactobacillus gasseri and Lactobacillus rhamnosus) or active control treatment (clotrimazole in candida vulvovaginitis and clindamycin in bacterial vulvovaginitis). All treatments were administered vaginally. The study population comprised 48 women aged >18 years with a suspected diagnosis of vulvovaginitis. We excluded patients who were menstruating or breastfeeding and patients who were pregnant (or planning to become pregnant) at baseline. We also excluded patients who had taken antibiotic treatment or probiotic prophylaxis in the previous 2 weeks and treatments that could interfere with the study. Similarly, we excluded patients infected by Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, or Herpes simplex. Follow-up lasted 12 weeks and included 3 face-to-face contacts and 2 telephone calls. Results: Almost all patients (97.9%) were of childbearing age, 100% were sexually active, 77.1% had a history of vulvovaginitis, and 41.7% had recurrent vulvovaginitis. After treatment, the cure rate was 60.9% in the study treatment group and 62.5% in the control group. Vulvovaginitis improved in 39.1% and 33.3%, respectively, and no response was observed in 0% and 4.2% respectively, with no significant differences between the treatments. The Sobel score improved significantly (p<0.05) after 2 weeks of follow-up (study treatment, baseline=5.83±1.6 and 2 weeks=1.00±1.90; control treatment, baseline=6.13±3.03 and 2 weeks=1.30±2.72), although there were no significant differences between the groups. Conclusions: Administration of boric acid and probiotics for treatment of vulvovaginitis proved to be as effective as the standard treatment for candida and bacterial vulvovaginitis. Larger studies are needed to confirm our findings


Objetivo: Demostrar que la administración vaginal de ácido bórico y probióticos en vulvovaginitis oportunistas es un tratamiento eficaz, no solo como opción alternativa, sino también como primera opción terapéutica. Material y métodos: Ensayo piloto multicéntrico, abierto, con asignación aleatoria al tratamiento en estudio (150mg ácido bórico + L.gasseri y L.rhamnosus, AB+P) o al control (C) activo (clotrimazol en vulvovaginitis candidiásica y clindamicina en vulvovaginitis bacteriana), todos vía vaginal. Se incluyó 48 mujeres > 18 años, con diagnóstico de sospecha de vulvovaginitis. Se excluyó pacientes con menstruación, con lactancia, embarazadas (o susceptibles de embarazo) al inicio del estudio, con tratamiento antibiótico o profilaxis con probióticos en las 2 semanas previas y tratamientos que pudieran interferir. Se excluyó pacientes con infección por Chlamydia trachomatis, Trichomona vaginalis, Neisseria gonorrhoeae o Herpes simplex. Se siguieron 12 semanas con 3 controles presenciales y 2 telefónicos. Resultados: 97,9% estaban en edad fértil, 100% eran sexualmente activas, 77,1% tenía antecedentes de vulvovaginitis y 41,7% sufría vulvovaginitis recurrentes. Tras el tratamiento, se logró resolución en un 60,9% con AB+P y un 62,5% con C, mejoría en 39,1% y 33,3% y ausencia de respuesta en 0% y 4,2% respectivamente, sin diferencias significativas entre tratamientos. Sobel score mostró mejoría significativa (p<0,05) tras 2 semanas de seguimiento (AB+P: basal=5,83±1,6 y 2sems=1,00±1,90, C: basal=6,13±3,03 y 2sems=1,30±2,72) sin diferencias entre grupos. Conclusiones: El tratamiento de vulvovaginitis con ácido bórico y probióticos resultó un recurso terapéutico igual de eficaz que los tratamientos estándar para vulvovaginitis candidiásica y bacteriana. Estudios más amplios podrían confirmarlo


Assuntos
Humanos , Feminino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Ácidos Bóricos/uso terapêutico , Probióticos/uso terapêutico , Vulvovaginite/tratamento farmacológico , Micoses/tratamento farmacológico , Infecções Bacterianas/tratamento farmacológico , Candidíase Vulvovaginal/tratamento farmacológico , Resultado do Tratamento
3.
World Neurosurg ; 122: e989-e994, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30399469

RESUMO

BACKGROUND: Epidural fibrosis is a major problem after spine surgery, with some patients having recurrent symptoms secondary to excessive formation of scar tissue resulting in neurologic compression. We used a rat laminectomy model to determine if topical application of boric acid could be helpful in the prevention of epidural fibrosis. METHODS: Rats were randomly assigned to 2 control and 2 experimental groups (n = 8 for each group). The negative control group received no surgery, and the positive control group underwent laminectomy only. Experimental groups were classified according to the study agents applied onto the dura mater after laminectomy at the L3 level: 2.5% boric acid solution and 5% boric acid solution. The extent of epidural fibrosis was assessed 4 weeks later macroscopically and histopathologically. RESULTS: Boric acid reduced epidural fibrosis in rats after laminectomy. The effect of 5% boric acid solution was more pronounced (P < 0.05) compared with the 2.5% solution. CONCLUSIONS: The antifibrotic effect of boric acid solution for the prevention of epidural fibrosis suggests that boric acid should be further evaluated in future studies for the prevention of epidural fibrosis.


Assuntos
Antifibrinolíticos/uso terapêutico , Ácidos Bóricos/uso terapêutico , Cicatriz/tratamento farmacológico , Espaço Epidural/efeitos dos fármacos , Animais , Antifibrinolíticos/farmacologia , Ácidos Bóricos/farmacologia , Cicatriz/etiologia , Cicatriz/patologia , Relação Dose-Resposta a Droga , Espaço Epidural/patologia , Fibrose , Laminectomia/efeitos adversos , Masculino , Complicações Pós-Operatórias/tratamento farmacológico , Complicações Pós-Operatórias/etiologia , Complicações Pós-Operatórias/patologia , Distribuição Aleatória , Ratos , Ratos Wistar , Resultado do Tratamento
4.
Oral Maxillofac Surg ; 22(4): 443-450, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30345483

RESUMO

PURPOSE: Augmentation of the maxillary sinus floor with bone grafting is commonly used for successful treatment of edentulous posterior maxilla with dental implants, and it is essential to maintain good bone volume and quality for long-term success of dental implants. The aim of this experimental study was to investigate the local and systemic effects of boric acid on new bone formation after maxillary sinus floor augmentation (MSFA). MATERIALS AND METHODS: Twenty-four male, New Zealand rabbits were randomly divided into three groups with eight rabbits each, and bilateral MSFA was performed in each animal. An autogenous bone/xenograft mixture was used to augment the maxillary sinuses in each group. Group 1 was determined as control with no additional materials, whereas 3 mg/kg boric acid (BA) was added to the mixture in group 2, and 3 mg/kg boric acid solution added to drinking water daily in group 3. RESULTS: The animals were sacrificed and also histologic, histomorphometric, and immunnohistochemical analyses were performed at weeks 4 and 8. At week 4, bone regeneration was better in the local BA group than in the control and systemic BA groups (p < 0.05). However, no significant difference was found among the groups in terms of bone regeneration at the end of week 8 (p > 0.05). CONCLUSION: Significant higher new bone formation was revealed by BA at early healing especially with local application. BA may be a therapeutic option for improving the bone regeneration.


Assuntos
Ácidos Bóricos/uso terapêutico , Osteogênese/efeitos dos fármacos , Levantamento do Assoalho do Seio Maxilar/métodos , Administração Oral , Animais , Substitutos Ósseos/administração & dosagem , Substitutos Ósseos/uso terapêutico , Transplante Ósseo/métodos , Ácidos Bóricos/administração & dosagem , Masculino , Seio Maxilar/anatomia & histologia , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/cirurgia , Coelhos
5.
Med Hypotheses ; 118: 78-83, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-30037620

RESUMO

Boron is increasingly added to food supplements due to multiple effects that have been reported in mammals after boric acid administration. Among these effects are inflammatory process control, bone and muscle strength enhancement, protein expression regulation, and a decreased risk of developing some pathologies in which these processes are key, such as osteoporosis, dermatological inflammatory non-infectious maladies and diseases affecting the central nervous system. Experimental data have suggested that steroid hormone levels in plasma change after boric acid administration, but a clear mechanism behind these variations has not been established. We analyzed possibilities for these changes and hypothesized that boric acid disrupts the interactions between steroid hormones and several carriers in plasma. In particular, we proposed that there is an uncoupling of the interactions between sex hormone binding globulin (SHBG) and estrogens and testosterone and that there are alterations in the binding of hydrophobic ligands by other carrier proteins in plasma. Further experimental and computational studies are required to support the hypothesis that boric acid and probably other boron-containing compounds can displace steroid hormones from their plasma carriers. If such phenomena are confirmed, boron administration with a clear mechanism could be employed as a therapeutic agent in several diseases or physiological events that require modulation of steroid hormone levels in plasma.


Assuntos
Boro/uso terapêutico , Globulina de Ligação a Hormônio Sexual/metabolismo , Esteroides/uso terapêutico , Ácidos Bóricos/química , Ácidos Bóricos/uso terapêutico , Boro/química , Proteínas de Transporte/metabolismo , Estrogênios/metabolismo , Glicoproteínas/metabolismo , Humanos , Inflamação/etiologia , Ligantes , Modelos Teóricos , Osteoporose/etiologia , Multimerização Proteica , Testosterona/metabolismo
6.
Expert Opin Pharmacother ; 19(9): 971-977, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29932786

RESUMO

INTRODUCTION: Clinicians are increasingly challenged by patients with refractory vulvovaginal candidiasis (VVC) caused by azole-resistant Candida species. Fluconazole resistant C.albicans is a growing and perplexing problem following years of indiscriminate drug prescription and unnecessary drug exposure and for which there are few therapeutic alternatives. Regrettably, although the azole class of drugs has expanded, new classes of antifungal drugs have not been forthcoming, limiting effective treatment options in patients with azole resistant Candida vaginitis. AREAS COVERED: This review covers published data on epidemiology, pathophysiology and treatment options for women with azole-resistant refractory VVC. EXPERT OPINION: Fluconazole resistant C.albicans adds to the challenge of azole resistant non-albicans Candida spp. Both issues follow years of indiscriminate drug prescription and unnecessary fluconazole exposure. Although an understanding of azole resistance in yeast has been established, this knowledge has not translated into useful therapeutic advantage. Treatment options for such women with refractory symptoms are extremely limited. New therapeutic options and strategies are urgently needed to meet this challenge of azole drug resistance.


Assuntos
Antifúngicos/uso terapêutico , Candidíase Vulvovaginal/tratamento farmacológico , Fluconazol/uso terapêutico , Inibidores de 14-alfa Desmetilase/farmacologia , Inibidores de 14-alfa Desmetilase/uso terapêutico , Antifúngicos/farmacologia , Ácidos Bóricos/farmacologia , Ácidos Bóricos/uso terapêutico , Candida/efeitos dos fármacos , Candida/isolamento & purificação , Candidíase Vulvovaginal/microbiologia , Candidíase Vulvovaginal/patologia , Farmacorresistência Fúngica/efeitos dos fármacos , Feminino , Fluconazol/farmacologia , Humanos , Testes de Sensibilidade Microbiana
7.
Inflammation ; 41(3): 1032-1048, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29500724

RESUMO

The development of treatment protocols that can reduce side effects in chemotherapy applications is extremely important in terms of cancer treatment. In this context, it was aimed to investigate the effects of boric acid and borax on cisplatin toxicity (nephrotoxicity) in rats. In the experimental phase, eight groups were formed from rats. Boric acid and borax were given to the treatment groups with three different doses using gavage. On the fifth day of the study, cisplatin (10 mg/kg) was administered to all rats except the control group. At the end of the study, oxidative stress-related (GSH, MDA, PCO, GPx, 8-OHdG), inflammation-related (TNF-α, IL-1ß, IL-18, MCP-1, ICAM, TGF-ß), apoptosis-related (p53, caspase 1, 3, 8, 12, bcl-2, bcl-xL, NFkB), and ER stress-related (GRP78, ATF-6, PERK) basic parameters were analyzed in serum, erythrocyte, and kidney tissues. Kidney tissues were also examined by histopathological and immunohistochemical methods. Borax and boric acid at different doses decreased inflammation and oxidative stress caused by cisplatin toxicity and increased ER stress. As a result of the treatments applied to experimental animals, it was determined that boric acid and borax reduced apoptotic damage in kidney tissue, but the decrease was statistically significant only in 200 mg/kg boric acid-administered group. In the study, low anti-apoptotic effects of borate doses with the anti-inflammatory and antioxidant effect may be due to increased ER stress at the relevant doses. Further studies on the effects of boron compounds on ER stress and apoptotic mechanisms may clarify this issue. Thus, possible side effects or if there are new usage areas of borone compounds which have many usage areas in clinics can be detected.


Assuntos
Apoptose/efeitos dos fármacos , Boratos/farmacologia , Ácidos Bóricos/farmacologia , Citotoxinas/antagonistas & inibidores , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Animais , Boratos/uso terapêutico , Ácidos Bóricos/uso terapêutico , Cisplatino/toxicidade , Relação Dose-Resposta a Droga , Inflamação/tratamento farmacológico , Ratos
8.
Int J STD AIDS ; 29(8): 825-827, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29393008

RESUMO

This study presents a case report of a female patient with symptomatic refractory Trichomonas vaginalis infection who was not able to clear her infection with high-dose oral metronidazole, oral tinidazole, intra-vaginal zinc sulfate, intra-vaginal metronidazole, intra-vaginal tinidazole, and intra-vaginal boric acid. She was unable to tolerate intra-vaginal paromomycin. A combination of intravenous metronidazole, oral tinidazole liquid suspension, and intra-vaginal boric acid for 14 days subsequently achieved a complete symptomatic and laboratory cure.


Assuntos
Antiprotozoários/administração & dosagem , Antitricômonas/administração & dosagem , Ácidos Bóricos/administração & dosagem , Metronidazol/administração & dosagem , Tinidazol/administração & dosagem , Vaginite por Trichomonas/tratamento farmacológico , Trichomonas vaginalis/efeitos dos fármacos , Administração Intravaginal , Administração Intravenosa , Adulto , Antiprotozoários/uso terapêutico , Antitricômonas/uso terapêutico , Ácidos Bóricos/uso terapêutico , Feminino , Derivação Gástrica , Humanos , Metronidazol/uso terapêutico , Tinidazol/uso terapêutico , Resultado do Tratamento , Trichomonas vaginalis/isolamento & purificação
9.
Sex Transm Infect ; 94(8): 574-577, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-29223972

RESUMO

OBJECTIVES: Trichomoniasis, caused by Trichomonas vaginalis (TV), is the most common curable sexually transmitted infection worldwide. Current guidance in the UK is to treat TV with a nitroimidazole antibiotic. The high prevalence of TV, high rate of antibiotic resistance and limited tolerability to nitroimidazoles suggest that alternative treatment regimens are needed. Intravaginal boric acid (BA) has been used safely for the treatment of candida vulvovaginitis and bacterial vaginosis, and in vitro studies suggest BA is active against TV. We review the evidence for the efficacy of BA in patients with TV. METHODS: MEDLINE, EMBASE, CINAHL, AMED, HMIC and BNI and Grey literature databases, The Cochrane Library, Trial Registers, conference abstracts and proceedings were searched. Inclusion criteria were women aged 16 years or over with microbiological confirmation of TV infection and using BA as treatment. There were no restrictions on language, publication date or study design. The in vitro evidence for BA activity against TV was also reviewed. RESULTS: No randomised controlled trials or case series were found. Four case reports demonstrated TV clearance with BA using a variety of dose regimens (dose 600 mg alternate nights to 600 mg two times per day; duration 1-5 months). In vitro studies suggest that BA has activity against TV which is independent of its effect on pH. DISCUSSION: Further evaluation of BA for the treatment of uncomplicated TV is required, but it may be useful when therapeutic options are limited. If shown to be safe and effective, intravaginal BA might provide a well-tolerated alternative anti-infective treatment which reduces community exposure to systemic antibiotics.


Assuntos
Antiprotozoários/efeitos adversos , Antiprotozoários/uso terapêutico , Ácidos Bóricos/efeitos adversos , Ácidos Bóricos/uso terapêutico , Vaginite por Trichomonas/tratamento farmacológico , Trichomonas vaginalis/efeitos dos fármacos , Administração Intravaginal , Adulto , Feminino , Humanos , Adulto Jovem
10.
J Investig Clin Dent ; 9(1)2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28631896

RESUMO

AIM: Boric acid (BA) exhibits antibacterial, anti-inflammatory, as well as osteoblastic, activity. The aim of the present study was to explore the efficacy of 0.75% BA gel as a local drug-delivery system in adjunct to scaling and root planing (SRP) for the treatment of class II furcation defects in comparison with placebo gel. METHODS: A total of 48 mandibular class II furcation defects were randomized and treated with either 0.75% BA gel or placebo gel. Clinical parameters were recorded at baseline, 3 months, and 6 months, while radiographic parameters were recorded at baseline and 6 months. RESULTS: Greater mean probing depth reduction and mean relative vertical and horizontal clinical attachment level gain were shown to be greater in group 1 than in group 2 at 3 and 6 months. Furthermore, a significantly greater mean percentage of bone fill was found in group 1 (16.98%±1.03%) than in the placebo (2.86%±0.92%) at 6 months. CONCLUSION: The .75% BA group showed significant improvement in clinical parameters compared to placebo gel as an adjunct to SRP. This implies an alternative for treatment of class II furcation.


Assuntos
Ácidos Bóricos/administração & dosagem , Ácidos Bóricos/uso terapêutico , Periodontite Crônica/tratamento farmacológico , Sistemas de Liberação de Medicamentos/métodos , Defeitos da Furca/tratamento farmacológico , Administração Oral , Adulto , Regeneração Óssea/efeitos dos fármacos , Índice de Placa Dentária , Raspagem Dentária , Feminino , Defeitos da Furca/diagnóstico por imagem , Géis , Humanos , Masculino , Mandíbula , Pessoa de Meia-Idade , Osteoblastos/efeitos dos fármacos , Índice Periodontal , Bolsa Periodontal/tratamento farmacológico , Aplainamento Radicular , Resultado do Tratamento
11.
J Investig Clin Dent ; 9(1)2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28474437

RESUMO

AIM: Borinic acid quinoline esters are a recently-identified class of new antibacterial and anti-inflammatory compounds known to inhibit osteoclastic bone resorption. They have proposed to have osteostimulative properties by causing osteoblast differentiation in vivo and in vitro. The purpose of this double-masked, randomized, controlled clinical trial was to evaluate the effects of the subgingival delivery of boric acid gel as an adjunct to scaling and root planing (SRP) on clinical and radiographic parameters, and compare this method with SRP plus placebo gel alone in chronic periodontitis (CP) patients. METHODS: Thirty-nine systemically-healthy patients with CP were included in the present study. They were divided into two groups: (a) SRP + 0.75% boric acid gel (BA group); and (b) SRP + placebo gel (placebo group). At baseline, 3 and 6 months after treatment, clinical measurements, including plaque index, modified sulcus bleeding index, probing depth (PD), clinical attachment level (CAL), intrabony defect depth, and percentage change in radiographic defect depth reduction (DDR%) as radiographic parameters were assessed. RESULTS: The mean PD reduction and mean CAL gain were greater in the BA group than the placebo group at 3 and 6 months. A significantly greater mean percentage of radiographic DDR% was found in the BA group (36.97±3.47%) compared to the placebo group (2.88±0.89%) after 6 months. CONCLUSION: BA as an adjunct to SRP can provide a new insight into therapeutic strategies for the management of CP, but further clinical evaluations are needed.


Assuntos
Ácidos Bóricos/administração & dosagem , Ácidos Bóricos/uso terapêutico , Periodontite Crônica/tratamento farmacológico , Administração Oral , Periodontite Crônica/diagnóstico por imagem , Índice de Placa Dentária , Raspagem Dentária/métodos , Método Duplo-Cego , Feminino , Géis , Hemorragia Gengival/terapia , Humanos , Índia , Masculino , Perda da Inserção Periodontal/terapia , Índice Periodontal , Bolsa Periodontal/terapia , Aplainamento Radicular/métodos , Resultado do Tratamento
12.
Can J Physiol Pharmacol ; 96(4): 404-411, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28898587

RESUMO

The harmful use of alcohol is a worldwide problem involving all ages. This study aims to investigate chronic alcohol exposure related hepatotoxicity on the rat liver and possible hepatoprotective effects of boric acid. Rats were separated into 4 different groups: control, ethanol, ethanol+boric acid, and boric acid. We measured (i) malondialdehyde (MDA), total sialic acid (TSA), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) levels, which are known to be the markers of alcohol damage; and also (ii) caspase-3, tumor necrosis factor-alpha (TNF-α), and the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) as the markers of apoptosis. In the ethanol group, MDA, TSA, and TNF-α levels increased whereas SOD and CAT levels decreased compared with the control group. Ethanol+boric acid group MDA, TSA, caspase-3, and TNF-α levels decreased whereas SOD and CAT levels increased compared with the ethanol group. Using histopathological evaluation of light microscope images, immunohistochemical caspase-3 and TNF-α activity in the ethanol+boric acid group were shown to be decreased compared with that in the ethanol group. Our results revealed that ethanol is capable of triggering oxidative stress and apoptosis in the rat liver. We propose that boric acid is an effective compound in protecting the rat liver against ethanol.


Assuntos
Antioxidantes/uso terapêutico , Apoptose , Ácidos Bóricos/uso terapêutico , Etanol/efeitos adversos , Hepatopatias/tratamento farmacológico , Animais , Antioxidantes/farmacologia , Apoptose/efeitos dos fármacos , Ácidos Bóricos/farmacologia , Caspase 3/metabolismo , Etanol/sangue , Comportamento Alimentar , Marcação In Situ das Extremidades Cortadas , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Hepatopatias/sangue , Hepatopatias/patologia , Masculino , Ratos Sprague-Dawley , Coloração e Rotulagem , Fator de Necrose Tumoral alfa/metabolismo
14.
J Laryngol Otol ; 130(9): 811-5, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27477534

RESUMO

OBJECTIVES: To compare the clinical effectiveness and adverse events for 3 per cent boric acid in 70 per cent alcohol versus 1 per cent clotrimazole solution in the treatment of otomycosis. METHODS: A total of 120 otomycosis patients were randomly assigned to receive either 1 per cent clotrimazole solution (intervention group) or 3 per cent boric acid in 70 per cent alcohol (control group) at the Khon Kaen Hospital ENT out-patient department. Treatment effectiveness was determined based on the otomicroscopic absence of fungus one week after therapy, following a single application of treatment. RESULTS: After 1 week of treatment, there were data for 109 participants, 54 in the clotrimazole group and 55 in the boric acid group. The absolute difference in cure rates between 1 per cent clotrimazole solution and 3 per cent boric acid in 70 per cent alcohol was 17.9 per cent (95 per cent confidence interval, 2.3 to 33.5; p = 0.028) and the number needed to treat was 6 (95 per cent confidence interval, 3.0 to 43.4). Adverse events for the two agents were comparable. CONCLUSION: One per cent clotrimazole solution is more effective than 3 per cent boric acid in 70 per cent alcohol for otomycosis treatment.


Assuntos
Antifúngicos/uso terapêutico , Ácidos Bóricos/uso terapêutico , Clotrimazol/uso terapêutico , Otomicose/tratamento farmacológico , Adulto , Antifúngicos/administração & dosagem , Ácidos Bóricos/administração & dosagem , Clotrimazol/administração & dosagem , Meato Acústico Externo , Feminino , Humanos , Instilação de Medicamentos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
15.
J Low Genit Tract Dis ; 20(1): 85-9, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26083330

RESUMO

OBJECTIVES: The aims of this study are to analyze a cohort of women with vulvovaginal symptoms and positive cultures for non-albicans Candida (NAC) to determine whether yeast was responsible for their symptoms and to evaluate the mycological effectiveness of various regimens. METHODS: This observational study was performed from retrospective chart review of patients with positive NAC cultures between April 1, 2008, and January 31, 2011, at a tertiary care vaginitis center. Patient intake demographics were entered into a database. Follow-up visits were analyzed for data about patient treatments and outcomes. Patients were considered a clinical cure if their symptoms were significantly improved and mycologic cure (MC) if later yeast cultures were negative. If clinical symptoms improved at the same time as MC, the isolate was considered the proximate cause for the symptoms. RESULTS: One hundred eight patients meeting entry criteria were analyzed. Boric acid was effective at obtaining MC in 32 (78%) of 41 patients with C. glabrata, 3 of 3 patients with C. tropicalis, and 3 of 3 patients with C. lusitaniae. Fluconazole was effective as initial treatment for 3 (60%) of 5 patients with C. glabrata and 13 (81%) of 16 patients with C. parapsilosis. In 52.7% of C. glabrata, 66.7% of C. parapsilosis, and 57.1% of C. tropicalis cases, effective antifungal therapy led to symptom improvement. CONCLUSIONS: In a tertiary care vaginitis center, NAC, when isolated on culture, caused clinically significant infections in approximately half of symptomatic patients. A majority of infections can be effectively treated with boric acid or fluconazole regardless of the non-albicans Candida species.


Assuntos
Antifúngicos/uso terapêutico , Ácidos Bóricos/uso terapêutico , Candida/classificação , Candida/isolamento & purificação , Candidíase Vulvovaginal/tratamento farmacológico , Candidíase Vulvovaginal/microbiologia , Fluconazol/uso terapêutico , Adulto , Idoso , Candida/efeitos dos fármacos , Feminino , Humanos , Pessoa de Meia-Idade , Atenção Terciária à Saúde , Resultado do Tratamento
16.
Int J Pediatr Otorhinolaryngol ; 79(7): 1158-60, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26026892

RESUMO

Nontuberculous mycobacteria (NTM) are an increasingly recognized cause of chronic suppurative otitis media in children with tympanostomy tubes. Treatment of this condition is difficult and typically requires a combination of systemic antibiotics and surgical debridement. We present the first case of a 2-year-old male with chronic suppurative otitis media due to NTM who failed systemic antibiotic therapy and was successfully managed with topical boric acid powder. This report highlights the challenges involved in treating this infection, and introduces boric acid as a potentially valuable component of therapy.


Assuntos
Anti-Infecciosos Locais/uso terapêutico , Ácidos Bóricos/uso terapêutico , Infecções por Micobactéria não Tuberculosa/terapia , Otite Média Supurativa/microbiologia , Otite Média Supurativa/terapia , Administração Tópica , Pré-Escolar , Doença Crônica , Humanos , Masculino , Micobactérias não Tuberculosas , Pós
17.
Acta Odontol Scand ; 72(8): 729-36, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24720865

RESUMO

OBJECTIVE: The purpose of this study was to evaluate the effects of systemically administered boric acid on alveolar bone loss, histopathological changes and oxidant/antioxidant status in ligature-induced periodontitis in diabetic rats. MATERIALS AND METHODS: Forty-four Wistar rats were divided into six experimental groups: (1) non-ligated (NL, n = 6) group, (2) ligature only (LO, n = 6) group, (3) Streptozotocin only (STZ, n = 8) group, (4) STZ and ligature (STZ+LO, n = 8) group, (5) STZ, ligature and systemic administration of 15 mg/kg/day boric acid for 15 days (BA15, n = 8) group and (6) STZ, ligature and systemic administration of 30 mg/kg/day boric acid for 15 days (BA30, n = 8) group. Diabetes mellitus was induced by 60 mg/kg streptozotocin. Silk ligatures were placed at the gingival margin of lower first molars of the mandibular quadrant. The study duration was 15 days after diabetes induction and the animals were sacrificed at the end of this period. Changes in alveolar bone levels were clinically measured and tissues were histopathologically examined. Serum total antioxidant status (TAS), total oxidant status (TOS), calcium (Ca) and magnesium (Mg) levels and oxidative stress index (OSI) were evaluated. Primary outcome was alveolar bone loss. Seconder outcome (osteoblast number) was also measured. RESULTS: At the end of 15 days, the alveolar bone loss was significantly higher in the STZ+LO group compared to the other groups (p < 0.05). There was no significant difference in alveolar bone loss between the STZ+LO 15 mg/kg boric acid and STZ+LO 30 mg/kg boric acid groups (p > 0.05). Systemically administered boric acid significantly decreased alveolar bone loss compared to the STZ+LO group (p < 0.05). The osteoblast number in the BA30 group was significantly higher than those of the NL, STZ and STZ+LO groups (p < 0.05). Inflammatory cell infiltration was significantly higher in the STZ+LO group the other groups (p < 0.05). Serum TAS levels were significantly higher in the NL and LO groups than the other groups (p < 0.05). The differences in TOS levels were not found to be significant among all the groups (p > 0.05). The OSI values of the BA30 group were significantly lower than the STZ+LO group (p < 0.05). Also, the differences in serum calcium and magnesium levels were insignificant among the all groups (p > 0.05). CONCLUSION: Within the limits of this study, it can be suggested that BA, when administered systemically, may reduce alveolar bone loss in the diabetic rat model.


Assuntos
Perda do Osso Alveolar/tratamento farmacológico , Antioxidantes/uso terapêutico , Ácidos Bóricos/uso terapêutico , Diabetes Mellitus Experimental/complicações , Periodontite/tratamento farmacológico , Perda do Osso Alveolar/patologia , Animais , Antioxidantes/administração & dosagem , Ácidos Bóricos/administração & dosagem , Cálcio/sangue , Contagem de Células , Ligadura , Magnésio/sangue , Masculino , Doenças Mandibulares/tratamento farmacológico , Neutrófilos/patologia , Osteoblastos/efeitos dos fármacos , Osteoblastos/patologia , Osteoclastos/efeitos dos fármacos , Osteoclastos/patologia , Oxidantes/sangue , Estresse Oxidativo/fisiologia , Periodontite/patologia , Ratos , Ratos Wistar , Estreptozocina
19.
J Pediatr Gastroenterol Nutr ; 58(1): 61-7, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23942004

RESUMO

OBJECTIVE: The aim was to study the effects of boric acid (BA) and 2-aminoethoxydiphenyl borate (2-APB) on oxidative stress and inflammation in an experimental necrotizing enterocolitis (NEC) rat model. METHODS: Experimental NEC was induced in 40 newborn Sprague-Dawley rats by asphyxia and hypothermia applied in 3 consecutive days. Rats were subdivided into 4 subgroups as NEC, NEC+BA, NEC+2-APB, and controls. BA and 2-APB were applied daily before the procedure. Serum total antioxidant status, superoxide dismutase (SOD), tumor necrosis factor (TNF)-α, interleukin (IL)-6, and erythrocyte glutathione (GSH) levels were measured. Pathological changes for NEC in intestinal architecture were evaluated by a grading system. RESULTS: Pretreatment with BA and 2-APB resulted in a decrease in NEC incidence. In all of the NEC groups, decreased serum levels of GSH and SOD were measured. Boron limited GSH consumption but had no effect on SOD levels. Total antioxidant status levels were not statistically different among groups. In our experimental NEC model, BA, but not 2-APB, prevented the increase of TNF-α. Pretreatment with BA and 2-APB downregulated the activity levels of IL-6 in NEC. CONCLUSIONS: In the experimental NEC model, BA and 2-APB partly prevent NEC formation, modulate the oxidative stress parameters, bring a significant decrease in GSH consumption, and enhance the antioxidant defense mechanism, but have no effect on total antioxidant status. BA inhibits the hypoxia and hypothermia-induced increase in both IL-6 and TNF-a, but 2-APB only in IL-6. Boron may be beneficial in preventing NEC.


Assuntos
Anti-Inflamatórios/uso terapêutico , Antioxidantes/uso terapêutico , Ácidos Bóricos/uso terapêutico , Compostos de Boro/uso terapêutico , Enterocolite Necrosante/prevenção & controle , Inflamação/prevenção & controle , Estresse Oxidativo/efeitos dos fármacos , Animais , Animais Recém-Nascidos , Anti-Inflamatórios/farmacologia , Antioxidantes/metabolismo , Antioxidantes/farmacologia , Ácidos Bóricos/farmacologia , Compostos de Boro/farmacologia , Modelos Animais de Doenças , Regulação para Baixo , Enterocolite Necrosante/sangue , Enterocolite Necrosante/etiologia , Enterocolite Necrosante/patologia , Glutationa/sangue , Inflamação/sangue , Interleucina-6/sangue , Intestinos/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Superóxido Dismutase/sangue , Fator de Necrose Tumoral alfa/sangue
20.
J Periodontal Res ; 49(4): 472-9, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24033134

RESUMO

BACKGROUND AND OBJECTIVE: The goal of the present study was to evaluate the effects of systemic boric acid on the levels of expression of RANKL and osteoprotegerin (OPG) and on histopathologic and histometric changes in a rat periodontitis model. MATERIAL AND METHODS: Twenty-four Wistar rats were divided into three groups of eight animals each: nonligated (NL); ligature only (LO); and ligature plus treatment with boric acid (BA) (3 mg/kg per day for 11 d). A 4/0 silk suture was placed in a subgingival position around the mandibular right first molars; after 11 d the rats were killed, and alveolar bone loss in the first molars was histometrically determined. Periodontal tissues were examined histopathologically to assess the differences among the study groups. RANKL and OPG were detected immunohistochemically. RESULTS: Alveolar bone loss was significantly higher in the LO group than in the BA and NL groups (p < 0.05). The number of inflammatory infiltrate and osteoclasts in the LO group was significantly higher than that in the NL and BA groups (p < 0.05). The numbers of osteoblasts in LO and BA groups were significantly higher compared with NL group (p < 0.05). There were significantly more RANKL-positive cells in the LO group than in the BA and NL groups (p < 0.05). There was a higher number of OPG-positive cells in the BA group than in the LO and NL groups (p < 0.05). CONCLUSION: The present study shows that systemic administration of boric acid may reduce alveolar bone loss by affecting the RANKL/OPG balance in periodontal disease in rats.


Assuntos
Perda do Osso Alveolar/prevenção & controle , Ácidos Bóricos/uso terapêutico , Osteoprotegerina/efeitos dos fármacos , Ligante RANK/efeitos dos fármacos , Administração Oral , Perda do Osso Alveolar/patologia , Processo Alveolar/efeitos dos fármacos , Processo Alveolar/patologia , Animais , Ácidos Bóricos/administração & dosagem , Contagem de Células , Tecido Conjuntivo/patologia , Modelos Animais de Doenças , Fibroblastos/efeitos dos fármacos , Fibroblastos/patologia , Mandíbula/efeitos dos fármacos , Mandíbula/patologia , Osteoblastos/efeitos dos fármacos , Osteoblastos/patologia , Osteoclastos/efeitos dos fármacos , Osteoclastos/patologia , Ligamento Periodontal/efeitos dos fármacos , Ligamento Periodontal/patologia , Periodontite/etiologia , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA